233 related articles for article (PubMed ID: 24976690)
1. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Pina T; Ochoa R; González-Juanatey C; Llorca J; González-Gay MA
Mediators Inflamm; 2014; 2014():798060. PubMed ID: 24976690
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Palmou-Fontana N; Gómez-Acebo I; Blanco R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2014; 32(5):640-6. PubMed ID: 25190453
[TBL] [Abstract][Full Text] [Related]
3. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Arias-Bajo M; Rueda-Gotor J; Paz-Carreira J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):231-6. PubMed ID: 24295386
[TBL] [Abstract][Full Text] [Related]
4. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
[TBL] [Abstract][Full Text] [Related]
5. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):532-7. PubMed ID: 23484462
[TBL] [Abstract][Full Text] [Related]
6. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
[TBL] [Abstract][Full Text] [Related]
7. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2014; 32(2):218-24. PubMed ID: 24351434
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(5):749-55. PubMed ID: 23806325
[TBL] [Abstract][Full Text] [Related]
9. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Biomed Res Int; 2014; 2014():860651. PubMed ID: 24757680
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Mijares V; Carnero-López B; Gómez-Acebo I; Dierssen-Sotos T; Remuzgo-Martínez S; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Rheumatol Int; 2015 Dec; 35(12):2069-78. PubMed ID: 26143161
[TBL] [Abstract][Full Text] [Related]
11. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Clin Exp Rheumatol; 2013; 31(4):538-45. PubMed ID: 23711190
[TBL] [Abstract][Full Text] [Related]
12. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Genre F; López-Mejías R; Rueda-Gotor J; Miranda-Filloy JA; Ubilla B; Villar-Bonet A; Carnero-López B; Gómez-Acebo I; Blanco R; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Biomed Res Int; 2014; 2014():671061. PubMed ID: 25295265
[TBL] [Abstract][Full Text] [Related]
13. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.
Miranda-Filloy JA; Llorca J; Carnero-López B; González-Juanatey C; Blanco R; González-Gay MA
Clin Exp Rheumatol; 2012; 30(6):850-5. PubMed ID: 22765845
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.
Bes C; Yazici A; Soy M
Rheumatol Int; 2013 Jun; 33(6):1415-8. PubMed ID: 23143665
[TBL] [Abstract][Full Text] [Related]
16. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Gonzalez-Gay MA; Vazquez-Rodriguez TR; Garcia-Unzueta MT; Berja A; Miranda-Filloy JA; de Matias JM; Gonzalez-Juanatey C; Llorca J
Clin Exp Rheumatol; 2010; 28(1):56-62. PubMed ID: 20346239
[TBL] [Abstract][Full Text] [Related]
17. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.
Derdemezis CS; Filippatos TD; Voulgari PV; Tselepis AD; Drosos AA; Kiortsis DN
Clin Exp Rheumatol; 2010; 28(6):880-3. PubMed ID: 21122270
[TBL] [Abstract][Full Text] [Related]
18. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
[TBL] [Abstract][Full Text] [Related]
19. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy.
Kwon SR; Lim MJ; Suh CH; Park SG; Hong YS; Yoon BY; Kim HA; Choi HJ; Park W
Rheumatol Int; 2012 Aug; 32(8):2523-7. PubMed ID: 21833531
[TBL] [Abstract][Full Text] [Related]
20. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
